389 related articles for article (PubMed ID: 31438559)
1. ADAM17: An Emerging Therapeutic Target for Lung Cancer.
Saad MI; Rose-John S; Jenkins BJ
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31438559
[TBL] [Abstract][Full Text] [Related]
2. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
[TBL] [Abstract][Full Text] [Related]
3. EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cells.
Schumacher N; Thomsen I; Brundert F; Hejret V; Düsterhöft S; Tichý B; Schmidt-Arras D; Voss M; Rose-John S
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119489. PubMed ID: 37271223
[TBL] [Abstract][Full Text] [Related]
4. The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis.
Saad MI; McLeod L; Yu L; Ebi H; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
Carcinogenesis; 2020 Jun; 41(4):527-538. PubMed ID: 31257400
[TBL] [Abstract][Full Text] [Related]
5. Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 Confers Resistance to Colonic Inflammation Through EGFR Activation.
Shimoda M; Horiuchi K; Sasaki A; Tsukamoto T; Okabayashi K; Hasegawa H; Kitagawa Y; Okada Y
EBioMedicine; 2016 Mar; 5():114-24. PubMed ID: 27077118
[TBL] [Abstract][Full Text] [Related]
6. ADAM17 orchestrates Interleukin-6, TNFα and EGF-R signaling in inflammation and cancer.
Schumacher N; Rose-John S
Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119141. PubMed ID: 34610348
[TBL] [Abstract][Full Text] [Related]
7. ADAM17 and EGFR regulate IL-6 receptor and amphiregulin mRNA expression and release in cigarette smoke-exposed primary bronchial epithelial cells from patients with chronic obstructive pulmonary disease (COPD).
Stolarczyk M; Amatngalim GD; Yu X; Veltman M; Hiemstra PS; Scholte BJ
Physiol Rep; 2016 Aug; 4(16):. PubMed ID: 27561911
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the protease ADAM17 ameliorates experimental pancreatitis.
Saad MI; Weng T; Lundy J; Gearing LJ; West AC; Harpur CM; Alanazi M; Hodges C; Croagh D; Kumar B; Sagi I; Rose-John S; Jenkins BJ
Proc Natl Acad Sci U S A; 2022 Oct; 119(42):e2213744119. PubMed ID: 36215509
[TBL] [Abstract][Full Text] [Related]
9. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
Baumgart A; Seidl S; Vlachou P; Michel L; Mitova N; Schatz N; Specht K; Koch I; Schuster T; Grundler R; Kremer M; Fend F; Siveke JT; Peschel C; Duyster J; Dechow T
Cancer Res; 2010 Jul; 70(13):5368-78. PubMed ID: 20551051
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells.
Franchimont N; Lambert C; Huynen P; Ribbens C; Relic B; Chariot A; Bours V; Piette J; Merville MP; Malaise M
Arthritis Rheum; 2005 Jan; 52(1):84-93. PubMed ID: 15641051
[TBL] [Abstract][Full Text] [Related]
11. ADAM17: a molecular switch to control inflammation and tissue regeneration.
Scheller J; Chalaris A; Garbers C; Rose-John S
Trends Immunol; 2011 Aug; 32(8):380-7. PubMed ID: 21752713
[TBL] [Abstract][Full Text] [Related]
12. ADAM17 as a therapeutic target in multiple diseases.
Arribas J; Esselens C
Curr Pharm Des; 2009; 15(20):2319-35. PubMed ID: 19601834
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid induces tumor necrosis factor-alpha to regulate a pro-inflammatory cytokine network in ovarian cancer.
Wang W; Wu J; Mukherjee A; He T; Wang XY; Ma Y; Fang X
FASEB J; 2020 Oct; 34(10):13935-13948. PubMed ID: 32851734
[TBL] [Abstract][Full Text] [Related]
14. ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer.
Schumacher N; Rose-John S
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694340
[TBL] [Abstract][Full Text] [Related]
15. A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17.
Maretzky T; Zhou W; Huang XY; Blobel CP
Oncogene; 2011 Feb; 30(5):611-8. PubMed ID: 20871631
[TBL] [Abstract][Full Text] [Related]
16. Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation.
Schumacher N; Schmidt S; Schwarz J; Dohr D; Lokau J; Scheller J; Garbers C; Chalaris A; Rose-John S; Rabe B
J Immunol; 2016 Nov; 197(9):3705-3715. PubMed ID: 27698010
[TBL] [Abstract][Full Text] [Related]
17. The role of ADAM17 during liver damage.
Al-Salihi M; Bornikoel A; Zhuang Y; Stachura P; Scheller J; Lang KS; Lang PA
Biol Chem; 2021 Aug; 402(9):1115-1128. PubMed ID: 34192832
[TBL] [Abstract][Full Text] [Related]
18. Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles.
Schumacher N; Meyer D; Mauermann A; von der Heyde J; Wolf J; Schwarz J; Knittler K; Murphy G; Michalek M; Garbers C; Bartsch JW; Guo S; Schacher B; Eickholz P; Chalaris A; Rose-John S; Rabe B
J Biol Chem; 2015 Oct; 290(43):26059-71. PubMed ID: 26359498
[TBL] [Abstract][Full Text] [Related]
19. The metalloprotease ADAM17 in inflammation and cancer.
Düsterhöft S; Lokau J; Garbers C
Pathol Res Pract; 2019 Jun; 215(6):152410. PubMed ID: 30992230
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma.
Ringel J; Jesnowski R; Moniaux N; Lüttges J; Ringel J; Choudhury A; Batra SK; Klöppel G; Löhr M
Cancer Res; 2006 Sep; 66(18):9045-53. PubMed ID: 16982746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
